Cell & Gene Therapy
Can Gilead shake up the ASCT-ineligible large B-cell lymphoma market?
Following first-line therapy, 30–40% of LBCL patients will either experience relapse or recurrence. Of this group, an estimated 50% will be ineligible for ASCT.